EASD: Additional Evidence Showed ABASAGLAR® (insulin glargine) Provided Safety and Efficacy Similar to Lantus® (y 2)

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about ABASAGLAR() (insulin glargine) as a treatment for patients with diabetes mellitus in adults, adolescents and children aged two years and above and reflects Lilly's current belief. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with the results to date or that ABASAGLAR() will receive additional regulatory approvals. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

CONTACT:Molly McCullyCommunications ManagerLilly DiabetesEmail: mccully_molly@lilly.com[mailto:mccully_molly@lilly.com] Phone: +1-317-478-5423

Ralph WarsinskyCorporate CommunicationsBoehringer Ingelheim GmbHEmail: press@boehringer-ingelheim.com[mailto:press@boehringer-ingelheim.com]Phone: +49 (6132) 77-7051

Logo -- http://photos.prnewswire.com/prnh/200312... [http://photos.prnewswire.com/prnh/200312...]

Logo -- http://photos.prnewswire.com/prnh/201108... [http://photos.prnewswire.com/prnh/201108...]

Web site: http://www.lilly.com/http://www.boehringer-ingelheim.com/